Grifols (GRFS) Gains from Investment Securities (2010 - 2020)
Grifols (GRFS) posted Gains from Investment Securities of $15.9 million for Q4 2016, up 315.09% quarter-over-quarter from -$7.4 million in Q3 2016, and up 174.85% year-on-year from $5.8 million in Q1 2016.
Grifols (GRFS) Gains from Investment Securities (2010 - 2020) Analysis & Trends
Grifols (GRFS) has reported Gains from Investment Securities for 5 consecutive years, with $15.9 million the latest figure, recorded in Q4 2016.
- Gains from Investment Securities for Q4 2016 came in at $15.9 million, up 174.85% year-over-year; the trailing twelve-month figure through Dec 2016 was -$12.8 million (up 27.13% YoY), and the FY2025 annual result was -$2.3 million, down 117.86% from the prior year.
- Gains from Investment Securities was $15.9 million for Q4 2016 at Grifols, up from -$7.4 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $473.1 million in Q2 2015 and troughed at -$469.3 million in Q1 2015.
- Average Gains from Investment Securities over 4 years is -$14.9 million, with a median of -$3.7 million recorded in 2012.
- Year-over-year, Gains from Investment Securities plunged 4193096.4% in 2013 and surged 174.85% in 2016.
- Over 4 years, Gains from Investment Securities stood at -$14265.8 in 2012, then plunged by 770741.21% to -$110.0 million in 2013, then soared by 80.65% to -$21.3 million in 2015, then soared by 174.85% to $15.9 million in 2016.
- Per Business Quant data, the three most recent Gains from Investment Securities figures were $15.9 million in Q4 2016, -$7.4 million in Q3 2016, and -$21.3 million in Q4 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 703.98 Mn |
| Mar 31, 2020 | 703.98 Mn |
| Dec 31, 2019 | 876.80 Mn |
| Dec 31, 2019 | 876.80 Mn |
| Mar 31, 2019 | 655.51 Mn |
| Mar 31, 2019 | 655.51 Mn |
| Dec 31, 2018 | 664.30 Mn |
| Dec 31, 2018 | 664.30 Mn |
| Jun 30, 2018 | -1.04 Bn |
| Jun 30, 2018 | -1.04 Bn |
| Mar 31, 2018 | 1.04 Bn |
| Mar 31, 2018 | 1.04 Bn |
| Dec 31, 2017 | 959.74 Mn |
| Dec 31, 2017 | 959.74 Mn |
| Jun 30, 2017 | -725.94 Mn |
| Jun 30, 2017 | -725.94 Mn |
| Mar 31, 2017 | 785.51 Mn |
| Mar 31, 2017 | 785.51 Mn |
| Dec 31, 2016 | 15.93 Mn |
| Dec 31, 2016 | 15.93 Mn |